An observational study in Smoking Cessation, Nicotine Addiction and Nicotine Dependence, sponsored by Centre Oscar Lambret. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Centre Oscar Lambret · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Smoking Cessation with a site in France — 8 open to participants now, 11 under way, 1 of them phase 3. Smoking Cessation · France.
Among the 48 studies in Smoking Cessation with a site in France, this one is one of 6 that started in 2022, is one of 5 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 44th registered.
1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.
Browse Smoking Cessation studies →8 of the 48 studies in Smoking Cessation with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 50–74
Institut du Cancer de Montpellier - Val d'Aurelle · Sites in France
Ages 18+
Groupe Hospitalier Mutualiste de Grenoble · Sites in France
Ages 18+
Poitiers University Hospital · Sites in France
Ages 18+
Poitiers University Hospital · Sites in France
Ages 18–25
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 216 across 116 observational studies indexed under Smoking Cessation.
Median enrollment 124 across the 43 interventional studies, 112 across the 5 observational. Of the 34 that completed or were terminated, 6 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 48 have an industry lead sponsor. The 10 most frequent:
Centre Oscar Lambret is the lead sponsor of 130 studies on the registry; 13 are open to participants now.
Centre Oscar Lambret has 1 study filed under Smoking Cessation — fewer than ten, so there is no comparison to draw.
3 of the studies in Smoking Cessation with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06910566Centre Oscar LambretFactors Sustaining Tobacco Abstinence in Cancer Patients Treated With Radio-chemotherapy or Radiotherapy | 2026-11 |
| NCT06988644Groupe Hospitalier Mutualiste de GrenobleImpact of a Counseling Consultation in the Workplace for Smoker Health Professionals | 2026-11-30 |
| NCT07198971Institut du Cancer de Montpellier - Val d'AurelleFeasibility Study Incorporating Music Therapy to Optimise the Smoking Cessation Process Coordinated by a Tobacco Addiction Nurse in Smoking Patients Being Treated for Cancer | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 48 studies in Smoking Cessation with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The TABAC STOP ORL POUMON study aims to evaluate the factors influencing long-term smoking cessation in patients with head and neck cancer (HNC) or lung cancer undergoing radiotherapy or chemoradiotherapy. This is a single-center observational study, following patients at 1, 6, and 12 months after treatment completion. The primary objective is to determine the proportion of abstinent patients at 6 months, while secondary objectives analyze factors influencing abstinence, smoking trajectories, and reasons for relapse. A total of 100 patients will be included to ensure robust statistical analysis.
The TABAC STOP ORL POUMON study is a prospective, single-center observational study aiming to understand factors influencing long-term smoking cessation in patients treated for head and neck or lung cancer. Tobacco is a leading cause of death and disease, particularly in areas like Hauts-de-France with high smoking rates.
Eligible patients, undergoing radiotherapy or chemoradiotherapy, are enrolled during the final week of treatment, completing questionnaires assessing nicotine dependence and alcohol use. Follow-ups are scheduled at 1, 6, and 12 months, through clinic visits or phone interviews.
The primary endpoint is the proportion of patients who remain smoke-free at 6 months. Secondary endpoints include factors influencing smoking cessation, reasons for relapse, and changes in nicotine and alcohol dependence. The study will enroll 100 patients, expecting 81 evaluable cases, with data quality ensured through regular checks and source verification.
The study population consists of patients diagnosed with head and neck cancer (HNC) or lung cancer, who are undergoing curative treatment with chemoradiotherapy, radiotherapy alone, or stereotactic radiotherapy at the Centre Oscar Lambret in Lille, France. Participants are current or former smokers and are recruited during the last week of their radiotherapy treatment. The study aims to evaluate factors associated with maintaining tobacco abstinence in this specific patient population, focusing on their smoking cessation journey following cancer treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with human papillomavirus (HPV) may also be included
Exclusion Criteria :
Study Exit Criteria :
- Protocol-defined exit : After the 12-month consultation
Early exit :
Patients included in the study receive standard treatment with chemoradiotherapy or radiotherapy alone for their head and neck cancer or lung cancer. These treatments are part of their routine care and are not part of the observational study.
Also known as: chemoradiotherapy, radiotherapy
Abstinence at 1 month and 6 months after the end of treatment
The primary outcome measure will be abstinence at 1 month (physical consultation or telephone follow-up) and at 6 months after the end of treatment.
Time frame: 1 and 6 months after the end of treatment.
Proportion of patients willing to attend a smoking cessation consultation
Evaluation of patients willing to attend a smoking cessation consultation (assessed among active smokers at the phone follow-up consultation).
Time frame: At the 1-month telephone follow-up after the end of treatment.
Abstinence at 1 month after the end of treatment
Proportion of tobacco-abstinent patients 1 month after the end of radiotherapy or chemoradiotherapy
Time frame: 1 month after the end of treatment
Abstinence at 6 months after the end of treatment
Proportion of tobacco-abstinent patients 6 months after the end of radiotherapy or chemoradiotherapy
Time frame: 6 months after the end of treatment
Abstinence at 12 months after the end of treatment
Proportion of tobacco-abstinent patients 12 months after the end of radiotherapy or chemoradiotherapy
Time frame: 12 months after the end of treatment
Cigarette dependence (Cigarette Dependence Scale, CDS)
Level of nicotine dependence assessed using the Cigarette Dependence Scale (CDS). The CDS is a validated 12-item scale with scores ranging from 0 to 60, where higher scores indicate dependence.
Time frame: Baseline
Alcohol use and dependence (Alcohol Use Disorders Identification Test, AUDIT)
Alcohol consumption and dependence assessed using the Alcohol Use Disorders Identification Test (AUDIT). The AUDIT is a 10-item scale with scores ranging from 0 to 40, where higher scores indicate higher risk of alcohol-related harm.
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2022 (actual). Primary completion is estimated for Nov 2026, 56 months after the start.
Of 42 non-industry observational studies under Smoking Cessation, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 56 months is above that.
Counting every sponsor, half of 47 studies reached it within 28 months; a quarter within 14 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.